MX2011009369A - 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. - Google Patents

2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Info

Publication number
MX2011009369A
MX2011009369A MX2011009369A MX2011009369A MX2011009369A MX 2011009369 A MX2011009369 A MX 2011009369A MX 2011009369 A MX2011009369 A MX 2011009369A MX 2011009369 A MX2011009369 A MX 2011009369A MX 2011009369 A MX2011009369 A MX 2011009369A
Authority
MX
Mexico
Prior art keywords
mercaptoquinoline
carboxamides
substituted
kcnq2
modulators
Prior art date
Application number
MX2011009369A
Other languages
English (en)
Spanish (es)
Inventor
Wolfgang Schroeder
Sven Kuehnert
Gregor Bahrenberg
Achim Kless
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40671387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011009369(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Publication of MX2011009369A publication Critical patent/MX2011009369A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/06—Anti-spasmodics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Addiction (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2011009369A 2009-03-12 2010-03-11 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. MX2011009369A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09003597 2009-03-12
PCT/EP2010/001509 WO2010102811A1 (de) 2009-03-12 2010-03-11 Substituierte 2-mercaptochinolin-3-carboxamide als kcnq2/3 modulatoren

Publications (1)

Publication Number Publication Date
MX2011009369A true MX2011009369A (es) 2011-09-27

Family

ID=40671387

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011009369A MX2011009369A (es) 2009-03-12 2010-03-11 2-mercaptoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.

Country Status (20)

Country Link
US (2) US20100234372A1 (enExample)
EP (1) EP2406229A1 (enExample)
JP (1) JP5727946B2 (enExample)
KR (1) KR20110132590A (enExample)
CN (1) CN102348692A (enExample)
AR (1) AR075824A1 (enExample)
AU (1) AU2010223513B2 (enExample)
BR (1) BRPI1008939A2 (enExample)
CA (1) CA2755004A1 (enExample)
CL (1) CL2011002209A1 (enExample)
CO (1) CO6410292A2 (enExample)
EC (1) ECSP11011348A (enExample)
IL (1) IL214945A0 (enExample)
MX (1) MX2011009369A (enExample)
NZ (1) NZ595625A (enExample)
PE (1) PE20120790A1 (enExample)
RU (1) RU2011141188A (enExample)
TW (1) TWI461197B (enExample)
WO (1) WO2010102811A1 (enExample)
ZA (1) ZA201107444B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3178067B2 (ja) 1991-02-26 2001-06-18 ぺんてる株式会社 スズ−ニッケル二元合金電気めっき液組成物
JP2012520246A (ja) * 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
TW201038565A (en) 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier
PL2609086T3 (pl) 2010-08-27 2015-07-31 Gruenenthal Gmbh Podstawione 2-okso- i 2-tiookso-dihydrochinolino-3-karboksyamidy jako modulatory KCNQ2/3
KR20130100300A (ko) 2010-08-27 2013-09-10 그뤼넨탈 게엠베하 Ｋｃｎｑ２／３ 조절제로서의 치환된 ２-옥시-퀴놀린-３-카복스아미드
BR112013005056A2 (pt) 2010-09-01 2016-05-31 Gruenenthal Gmbh 1-oxo-di-hidroisoquinolina-3-carboxamidas substituídas como moduladores kcnq2/3
CN104994857A (zh) 2012-10-11 2015-10-21 格吕伦塔尔有限公司 Tspo介导的疾病和/或障碍的治疗和/或预防
WO2014082737A1 (en) * 2012-11-28 2014-06-05 Grunenthal Gmbh Specific carboxamides as kcnq2/3 modulators
US9248122B2 (en) 2012-11-28 2016-02-02 Grünenthal GmbH Heteroquinoline-3-carboxamides as KCNQ2/3 modulators
KR102226587B1 (ko) * 2013-01-31 2021-03-11 버텍스 파마슈티칼스 인코포레이티드 나트륨 채널의 조절제로서의 퀴놀린 및 퀴나졸린 아미드
JP2016511237A (ja) 2013-02-01 2016-04-14 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 選択的ｈｄａｃ３阻害剤
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9353122B2 (en) 2013-02-15 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9688688B2 (en) 2013-02-20 2017-06-27 Kala Pharmaceuticals, Inc. Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
US9353123B2 (en) 2013-02-20 2016-05-31 Kala Pharmaceuticals, Inc. Therapeutic compounds and uses thereof
US9890173B2 (en) 2013-11-01 2018-02-13 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
KR20160099084A (ko) 2013-11-01 2016-08-19 칼라 파마슈티컬스, 인크. 치료 화합물의 결정질 형태 및 그의 용도
PH12015000236B1 (en) * 2015-07-06 2024-01-10 Samsung Electronics Co Ltd Electronic device for providing a calibrated keyboard configuration
WO2018048750A1 (en) 2016-09-08 2018-03-15 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
US10253036B2 (en) 2016-09-08 2019-04-09 Kala Pharmaceuticals, Inc. Crystalline forms of therapeutic compounds and uses thereof
EP3509421A4 (en) 2016-09-08 2020-05-20 Kala Pharmaceuticals, Inc. CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
EP3558992A4 (en) * 2016-12-15 2020-12-02 ONO Pharmaceutical Co., Ltd. TREK CHANNEL ACTIVATOR (K + CHANNELS ASSOCIATED WITH TWIK)
DE102018212006B3 (de) * 2018-07-18 2019-10-31 Universität Greifswald Thioether als Modulatoren von Kv7.2/Kv7.3-Kanälen
EP4580618A2 (en) * 2022-08-30 2025-07-09 Pannex Therapeutics Inc. Pannexin-1 modulators and methods of treating disorders in which pannexin-1 is implicated

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2706977A1 (de) 1977-02-18 1978-08-24 Hoechst Ag Benzoesaeuren und deren derivate sowie verfahren zu ihrer herstellung
FR2532939A1 (fr) * 1982-09-13 1984-03-16 Roussel Uclaf Nouveaux derives de l'acide 4-hydroxy 3-quinoleine carboxylique substitues en 2, leur preparation, leur application comme medicament, les compositions les renfermant et les nouveaux intermediaires obtenus
DE4032147A1 (de) 1990-10-10 1992-04-16 Bayer Ag Verwendung von substituierten 2-mercaptonicotinsaeurederivaten zur bekaempfung von endoparasiten, neue substituierte 2-mercaptonicotinsaeurederivate und verfahren zu ihrer herstellung
EP0716077A1 (de) 1994-12-08 1996-06-12 Ciba-Geigy Ag Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
WO1996026925A1 (en) 1995-03-01 1996-09-06 Banyu Pharmaceutical Co., Ltd. Arylthioacetamide derivatives
DE19738615A1 (de) * 1997-09-04 1999-03-11 Clariant Gmbh Neue Lichtschutzmittel auf Basis von sterisch gehinderten Aminen
DE19738616A1 (de) 1997-09-04 1999-03-11 Clariant Gmbh 4-Hydroxychinolin-3-carbonsäure-Derivate als Lichtschutzmittel
AU3033500A (en) * 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
EP1200086A4 (en) 1999-08-04 2009-05-27 Icagen Inc THERAPEUTIC OR PROPHYLACTIC METHODS OF PAIN AND ANXIETY
EP1208085B1 (en) 1999-08-04 2007-12-05 Icagen, Inc. Benzanilides as potassium channel openers
MXPA03007397A (es) * 2001-02-20 2003-12-04 Bristol Myers Squibb Co Moduladores de canales de potasio kcnq y uso de los mismos en tratamiento de migrana y enfermedades mecanicamente relacionadas.
CZ20032233A3 (cs) 2001-02-20 2004-12-15 Bristol-Myers Squibb Company Derivát 2,4-disubstituovaného pyrimidin-5-karboxamidu jako modulátor draslíkového kanálku KCNQ
US6593349B2 (en) 2001-03-19 2003-07-15 Icagen, Inc. Bisarylamines as potassium channel openers
AU2002256085A1 (en) * 2001-04-06 2002-10-21 Smithkline Beecham Corporation Quinoline inhibitors of hyak1 and hyak3 kinases
US20040110947A1 (en) 2002-09-17 2004-06-10 Pharmacia Corporation Aromatic liver X-receptor modulators
CA2505195C (en) 2002-12-23 2012-07-10 Icagen, Inc. Quinazolinones as potassium channel modulators
EP1449841A1 (en) 2003-02-19 2004-08-25 Bayer CropScience SA New fungicidal compounds
US7598412B2 (en) 2003-10-08 2009-10-06 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
KR20070006890A (ko) 2004-05-04 2007-01-11 화이자 인코포레이티드 오르토 치환된 아릴 또는 헤테로아릴 아마이드 화합물
CA2881078C (en) * 2004-06-24 2018-10-02 Vertex Pharmaceuticals Incorporated Modulators of atp-binding cassette transporters
EP1814856A1 (en) 2004-11-12 2007-08-08 Galapagos N.V. Nitrogen heteroaromatic compounds which bind to the active site of protein kinase enzymes
CA2599890C (en) 2005-03-03 2011-05-03 H. Lundbeck A/S Substituted pyridine derivatives
DE102005038947A1 (de) 2005-05-18 2006-11-30 Grünenthal GmbH Substituierte Benzo[d]isoxazol-3-yl-amin-Verbindungen und deren Verwendung in Arzneimitteln
US8133907B2 (en) 2005-07-20 2012-03-13 Eli Lilly And Company Pyridine derivatives as dipeptedyl peptidase inhibitors
US7915410B2 (en) 2005-09-09 2011-03-29 Bristol-Myers Squibb Company Acyclic IKur inhibitors
EP1951685A1 (en) 2005-11-18 2008-08-06 NeuroSearch A/S Novel quinazoline derivatives and their medical use
DE602007004638D1 (de) 2006-07-20 2010-03-18 Amgen Inc Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
CA2658190C (en) 2006-07-20 2013-01-29 Amgen Inc. Di-amino-substituted heterocyclic compounds and methods of use
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
DE102006049452A1 (de) 2006-10-17 2008-05-08 Grünenthal GmbH Substituierte Tetrahydropyrolopiperazin-Verbindungen und deren Verwendung in Arzneimitteln
KR20090083479A (ko) * 2006-11-28 2009-08-03 밸리언트 파마슈티컬즈 인터내셔널 칼륨 채널 조절제로서의 1,4 디아미노 이환 레티가빈 유사체
US8563566B2 (en) 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
CA2695331A1 (en) 2007-08-03 2009-02-12 F. Hoffmann-La Roche Ag Pyridinecarboxamide and benzamide derivatives as taar1 ligands
WO2009052078A1 (en) 2007-10-19 2009-04-23 Boehringer Ingelheim International Gmbh Ccr10 antagonists
TWI504395B (zh) * 2009-03-10 2015-10-21 Substituted 3-amino-2-mercaptoquinoline as a KCNQ2 / 3 modifier
JP2012520246A (ja) * 2009-03-10 2012-09-06 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング Ｋｃｎｑ２／３モジュレータとしての置換された３−アミノイソオキサゾロピリジン
TW201038565A (en) * 2009-03-12 2010-11-01 Gruenenthal Gmbh Substituted 2-mercapto-3-aminopyridines as KCNQ2/3 modulators
TWI475020B (zh) * 2009-03-12 2015-03-01 The substituted nicotine amide as a KCNQ2 / 3 modifier

Also Published As

Publication number Publication date
KR20110132590A (ko) 2011-12-08
EP2406229A1 (de) 2012-01-18
TW201034670A (en) 2010-10-01
TWI461197B (zh) 2014-11-21
CL2011002209A1 (es) 2012-02-10
US20120252841A1 (en) 2012-10-04
CO6410292A2 (es) 2012-03-30
AU2010223513A1 (en) 2011-11-03
ECSP11011348A (es) 2011-10-31
US20100234372A1 (en) 2010-09-16
NZ595625A (en) 2012-10-26
JP2012520249A (ja) 2012-09-06
PE20120790A1 (es) 2012-07-08
JP5727946B2 (ja) 2015-06-03
AR075824A1 (es) 2011-04-27
ZA201107444B (en) 2012-06-27
BRPI1008939A2 (pt) 2016-03-15
RU2011141188A (ru) 2013-04-20
CA2755004A1 (en) 2010-09-16
WO2010102811A1 (de) 2010-09-16
US8399673B2 (en) 2013-03-19
AU2010223513B2 (en) 2014-12-04
CN102348692A (zh) 2012-02-08
IL214945A0 (en) 2011-11-30

Similar Documents

Publication Publication Date Title
MX2011008262A (es) Espiroamidas sustituidas como moduladores de b1r:.
MX2011008825A (es) 3-aminoisoxazolopiridinas sustituidas como moduladores de kcnq2/3.
MX2009003382A (es) Derivados de sulfonamidas sustituidos.
MX2011008864A (es) Tetrahidroazolopirazinas sulfoniladas y su uso como productos medicinales.
MX2011008662A (es) 2-mercapto-3-aminopiridinas sustituidas como moduladores de kcnq2/3.
MX2011009338A (es) 3-amino-2-mercaptoquinolinas sustituidas como moduladores de kcnq2/3.
MX2013003309A (es) Compuestos de benzamida sustituidos.
TW200800968A (en) Sulfoximine-substituted pyrimidines, processes for production thereof and use thereof as drugs
ZA201107806B (en) Organisms for the production of 1,3-butanediol
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MX2010012298A (es) Activadores de glucocinasa.
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
CY1110209T1 (el) Υποκατεστημενες ενωσεις βενζο(d)ισοξαζολ-3-υλ-αμινης σαν αναλγητικα
MY160625A (en) Process for preparing pan-cdk inhibitors of the formula(i), and intermediates in the preparation
WO2008046581A3 (de) Substituierte tetrahydropyrrolopyrazin-verbindungen als inhibitoren der monoaminwiederaufnahme und deren verwendung in arzeimitteln
MX2012008141A (es) Compuestos y metodos.
PL1891004T3 (pl) Pentafluorosulfanylo-podstawiony związek i jego zastosowanie do wytwarzania środków leczniczych
MX2009007436A (es) Derivados espirociclicos de acido tetronico.
MY156769A (en) Heat-aging-resistant polyamides
TN2012000610A1 (en) Heterocyclic compounds, their preparation and their therapeutic application
MY158910A (en) Surface modified silicic acid semi-gels
MX2010010597A (es) Procesos para la preparacion de derivados de dioxina benzofusionados.
MX2009004983A (es) Pirazoles sustituidos, composiciones que los contienen, procedimiento de fabricacion y utilizacion.

Legal Events

Date Code Title Description
FG Grant or registration